Crescent Biopharma, Inc. (CBIO)
(Delayed Data from NSDQ)
$11.00 USD
-0.60 (-5.17%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $10.90 -0.10 (-0.91%) 6:30 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CBIO 11.00 -0.60(-5.17%)
Will CBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CBIO
Crescent Biopharma reports Q2 results
CBIO Financial Stability: Cash Reserves to Support Operations Through 2027
Crescent (CBIO) Completes Merger and Advances Cancer Therapeutics Initiative
Crescent Biopharma reports Q2 EPS ($4.93)